Intellia (NTLA) Q2 2026 earnings review
Major Overhang Cleared as Commercial Pivot Accelerates
Intellia delivered a massive de-risking quarter. The severe nex-z clinical hold—which paralyzed the stock in late 2025—is over. By linking the trial's liver toxicities to a specific HLA allele, Intellia found a genetic biomarker that allows them to screen out at-risk patients and successfully reinitiate Phase 3 enrollment. Concurrently, the lonvo-z program for HAE posted stellar Phase 3 data (87% attack reduction) and is on glide-path for a 2H26 BLA. Financials clearly show a company pivoting from R&D to commercialization: R&D expenses decelerated, while G&A jumped 39% YoY to fund the lonvo-z commercial buildout. A $195M equity raise extends the runway into 2028, bridging the gap to launch.
🐂 Bull Case
Discovering a specific genetic allele (HLA) responsible for the liver toxicity allows Intellia to bypass the FDA clinical hold via screening. This rescues their largest total addressable market (ATTR).
Phase 3 HAELO data showed a 62% complete attack-free rate and an 87% attack reduction over 6 months, proving the 'one-and-done' CRISPR value proposition.
🐻 Bear Case
By actively screening out and denying nex-z to patients with the specific HLA allele, Intellia is permanently reducing its Total Addressable Market for the ATTR indication.
While net loss per share 'improved' from -$0.98 to -$0.80 YoY, this was entirely driven by a 28% increase in share count (103M to 133M) following the $195M equity raise.
⚖️ Verdict: 🟢
Bullish. Identifying a genetic off-ramp for the nex-z clinical hold rescues the pipeline's biggest asset. Paired with strong Phase 3 data for lonvo-z and a runway extended to 2028, the core investment thesis is intact.
Key Themes
Nex-z Rescue via Precision Genomics
Reversing. The crisis from late 2025—when a patient death triggered an FDA clinical hold—has been genetically solved. A comprehensive analysis of over 600 patients proved that the highest liver transaminase elevations occurred only in patients carrying one specific human leukocyte antigen (HLA) allele. Intellia can now simply use HLA genotyping to screen out susceptible patients. This elegant, data-driven solution allowed them to successfully reinitiate Phase 3 enrollment.
Lonvo-z Efficacy Secures the 'One-and-Done' Thesis
Accelerating. The Phase 3 HAELO trial proved that in vivo CRISPR editing works in the real world. A single infusion reduced Hereditary Angioedema (HAE) attacks by 87% versus placebo. More importantly, 62% of patients were entirely attack-free and therapy-free for the 6-month evaluation period. This clinical profile heavily de-risks the expected 2H26 BLA submission and 1H27 commercial launch.
Balance Sheet Fortified to Cross the Commercial Chasm
Stable. The $195M April stock offering boosted cash to $628.4M. This extends the runway from 'mid-2027' to 'at least into 2028'. This is a critical driver because it guarantees Intellia can fully fund the U.S. commercial launch of lonvo-z (1H27) without needing to raise capital from a position of weakness.
Targeted Screening Shrinks Addressable Market
While the HLA allele discovery saves the nex-z program, it comes at a cost. Any ATTR patient carrying this specific allele will likely be permanently excluded from receiving nex-z. The company has not yet disclosed what percentage of the general population carries this allele, leaving a blind spot regarding how much the TAM has actually shrunk.
G&A Expense Acceleration Weighs on Margins
Accelerating. General and administrative expenses surged 39% YoY to $37.8 million (up from $27.2 million). While necessary for building out the lonvo-z commercial infrastructure and legal teams, this accelerating cost center will drag on profitability well past the initial 2027 launch phase.
Collaboration Revenue Deceleration
Decelerating. Collaboration revenue dropped 46% YoY, from $14.2 million in 25Q2 to $7.7 million in 26Q2. Management cited a reduction in revenue specifically from Regeneron. While Intellia's future lies in its wholly-owned assets, the rapid decay of collaboration cash flow puts even more pressure on the remaining cash balance.
Other KPIs
Decelerating. Down 15% from $97.0M in the prior year. This drop was driven by lower external trial costs as the Phase 3 HAELO study wrapped up, signaling a successful transition out of the heavy clinical trial expenditure phase for lonvo-z.
Stable. Up slightly from a $101.3M loss in 25Q2. The $14.4M decrease in R&D spend was entirely offset by the $10.6M increase in G&A and the $6.5M drop in collaboration revenue.
Guidance
Accelerating. Upgraded from the previous quarter's guidance of 'mid-2027'. The $195M capital raise ensures the company is fully funded beyond the 1H27 expected launch of lonvo-z.
Stable. The company remains perfectly on track with its prior guidance to submit the Biologics License Application to the FDA by the end of 2026, setting up a 1H27 commercial launch.
Stable. Following the lifting of the clinical hold, management remains confident they can finish enrolling the polyneuropathy trial before the end of the year.
Key Questions
HLA Allele Prevalence
What exact percentage of the ATTR patient population carries the HLA allele associated with the liver toxicity, and how does this mathematically impact your peak sales estimates for nex-z?
MAGNITUDE (ATTR-CM) Resumption Timeline
You successfully reinitiated enrollment across Phase 3 trials, but with the new HLA screening protocol, what is the revised timeline to complete enrollment for the much larger MAGNITUDE cardiomyopathy trial?
Regeneron Collaboration Trajectory
With collaboration revenue from Regeneron nearly halving year-over-year to $7.7M, what is the expected run-rate for this revenue stream over the next 12-18 months?